Digestive system infectious disorder
MONDO:0043424A viral, bacterial, fungal, or parasitic infectious process that affects the digestive system.
Also known as: digestive system infection, gastrointestinal infection, gastrointestinal system infection, infection of gastrointestinal tract
542 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
On-the-Spot hep c care at methadone clinics boosts cure rates
⭐️ CURE ⭐️ CompletedThis study tested whether offering hepatitis C (HCV) treatment right at methadone clinics helps more people get cured compared to sending them to outside specialists. Over 600 adults on opioid addiction therapy took part across 13 clinics in Ukraine. Some clinics provided simplif…
Phase: NA • Sponsor: Ukrainian Institute on Public Health Policy • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough hepatitis c: 4-Drug cocktail aims for cure in Non-Responders
⭐️ CURE ⭐️ CompletedThis study tested a combination of four drugs (asunaprevir, daclatasvir, ribavirin, and pegylated interferon) in 60 adults with hepatitis C genotype 4 who had not responded to standard treatment. The goal was to see if this stronger therapy could clear the virus completely, with …
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:06 UTC
-
Could a Lower-Dose polio vaccine help eradicate the disease?
⭐️ VACCINE ⭐️ CompletedThis study tests a hexavalent vaccine that protects against six diseases, including polio, but uses a lower dose of the inactivated polio vaccine (IPV). The goal is to see if this reduced-dose version works as well as the standard full-dose vaccine in infants. Around 1,500 health…
Phase: PHASE3 • Sponsor: Serum Institute of India Pvt. Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 03, 2026 00:00 UTC
-
New vaccine aims to protect infants from deadly diarrhea
⭐️ VACCINE ⭐️ CompletedThis study tests a new vaccine called Shigella4V, designed to protect against shigellosis, a severe diarrheal disease. Researchers are giving the vaccine to healthy adults, children, and 9-month-old infants to check its safety and whether it triggers a strong immune response. Dif…
Phase: PHASE1, PHASE2 • Sponsor: LimmaTech Biologics AG • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:03 UTC
-
New shigella vaccine shows promise in first human trials
⭐️ VACCINE ⭐️ CompletedThis study tested a new vaccine designed to protect against severe diarrhea caused by Shigella bacteria. The vaccine was first given to adults in Europe, then to adults, children, and infants in Africa. Researchers checked for side effects and measured immune responses to find th…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:01 UTC
-
New vaccine targets common food poisoning bug
⭐️ VACCINE ⭐️ CompletedThis early-stage trial tested a new vaccine (CJCV2) designed to protect against Campylobacter infection, a leading cause of foodborne illness. Fifty-nine healthy adults received three different doses of the vaccine, with or without an immune-boosting adjuvant (ALFQ). The main goa…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
New vaccine aims to train body to fight hepatitis b
⭐️ VACCINE ⭐️ CompletedThis early-stage trial tested a new two-part vaccine designed to treat chronic hepatitis B. It involved 26 healthy adults to check safety and immune response. The vaccine uses a protein first shot followed by a booster to teach the immune system to attack the virus.
Phase: PHASE1 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:02 UTC
-
Double-Dose vaccine may protect HIV patients from hepatitis b
⭐️ VACCINE ⭐️ CompletedThis study tested whether a double-dose hepatitis B vaccine (40 micrograms) works better than the standard dose (20 micrograms) in people with HIV who did not respond to earlier hepatitis B shots. The goal was to see if the stronger dose could help their immune system produce eno…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:04 UTC
-
HIV patients get new hope against hepatitis b with tailored vaccine strategy
⭐️ VACCINE ⭐️ CompletedThis study tested three different ways of giving the hepatitis B vaccine to 437 people with HIV whose CD4 counts were above 200. The goal was to see which schedule—standard dose, double dose, or skin injections—works best to protect them from hepatitis B, a virus that can cause s…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:04 UTC
-
Hexaxim vaccine safety confirmed in 713 infants
⭐️ VACCINE ⭐️ CompletedThis completed study checked the safety of the Hexaxim vaccine in 713 infants aged 2 months and older in South Korea. Researchers tracked side effects like injection site reactions, fever, and crying after routine vaccination. The goal was to confirm the vaccine's safety in every…
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:06 UTC
-
Cholera vaccine vaxchora put to the test in immune response study
⭐️ VACCINE ⭐️ CompletedThis phase 2 trial tested the oral cholera vaccine Vaxchora in 34 healthy adults to see how well it triggers protective antibodies and immune cells. Participants received a single dose, and researchers measured antibody levels, B cells, and T cell responses. The goal is to unders…
Phase: PHASE2 • Sponsor: Emory University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:04 UTC
-
New shigella vaccine shows promise for infants in phase 2 trial
⭐️ VACCINE ⭐️ CompletedThis study tested a new vaccine called Shigella4V2 to protect infants against shigellosis, a severe diarrheal disease. Researchers gave the vaccine to 110 healthy 9-month-old babies to check its safety and how well it triggers an immune response. The goal is to find the best dose…
Phase: PHASE2 • Sponsor: LimmaTech Biologics AG • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:03 UTC
-
New oral vaccine aims to tackle two Diarrhea-Causing bugs at once
⭐️ VACCINE ⭐️ CompletedThis early-stage study tested a new oral vaccine designed to protect against two bacteria that cause severe diarrhea: Shigella and ETEC. Fifty-three healthy adults received the vaccine to check for side effects and to see if it triggers an immune response. The goal is to develop …
Phase: PHASE1 • Sponsor: University of Maryland, Baltimore • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
New vaccine aims to stop deadly infant diarrhea
⭐️ VACCINE ⭐️ CompletedThis study tested a new Shigella vaccine in 200 healthy African infants to see if it can prevent severe diarrhea. The vaccine was given in two doses, and researchers measured immune responses and safety. The trial is now complete, and results will show whether this approach is pr…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
-
New combo vaccine targets deadly diarrhea in kids
⭐️ VACCINE ⭐️ CompletedThis study tested a new vaccine called ShigETEC in healthy adults and children in Bangladesh. The vaccine aims to protect against two bacteria that cause severe diarrhea: Shigella and ETEC. Researchers gave three doses of the vaccine or a placebo to 196 participants to check if i…
Phase: PHASE1 • Sponsor: Eveliqure Biotechnologies GmbH • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:13 UTC
-
Could fewer shots protect just as well? new study tests hepatitis b vaccine schedules for babies
⭐️ VACCINE ⭐️ CompletedThis study looked at whether giving young children 2 doses of the hepatitis B vaccine works as well as the usual 3 doses. Over 400 children aged 2 to 18 months took part. Researchers measured blood antibody levels to see if fewer shots still provide strong protection against the …
Phase: PHASE4 • Sponsor: Laval University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:13 UTC
-
New hepatitis b vaccine candidate shows promise in early trial
⭐️ VACCINE ⭐️ CompletedThis early-stage study tested a new hepatitis B vaccine that includes an experimental booster called AS37. The goal was to see if the vaccine is safe and how well it triggers the immune system. 122 healthy adults aged 18-45 received two doses one month apart. Researchers monitore…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:11 UTC
-
Can toddlers get three vaccines at once? new study says yes
⭐️ VACCINE ⭐️ CompletedThis study tested whether giving a booster polio vaccine (sIPV) at the same time as MMR and hepatitis A vaccines is safe and works well in toddlers. About 889 healthy children aged 18 to 22 months who had already received their first polio and MMR shots took part. Researchers che…
Phase: PHASE4 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:11 UTC
-
New 6-in-1 shot for babies shows promise in thai trial
⭐️ VACCINE ⭐️ CompletedThis study tested a new combination vaccine called Shan6™, which protects against six diseases (diphtheria, tetanus, whooping cough, hepatitis B, Hib, and polio) in healthy infants and toddlers in Thailand. The trial involved 460 participants and compared Shan6™ to a similar 5-in…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:51 UTC
-
Telehealth program aims to get HIV treatment to people who inject drugs faster
Disease control CompletedThis study tested two ways to offer HIV treatment, hepatitis C treatment, and substance use disorder medications to people who inject drugs. One group received a telehealth-enhanced program with on-demand services like mobile blood draws and counseling, while the other group got …
Phase: NA • Sponsor: University of Miami • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
Disease control CompletedThis study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if d…
Phase: PHASE2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug naderin may help patients fight infections during cancer and TB therapy
Disease control CompletedThis study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. …
Phase: PHASE2, PHASE3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hepatitis b drug shows promise in first human tests
Disease control CompletedThis early-phase trial tested an experimental drug called BW-20507 in 32 people. First, healthy volunteers received a single dose to check safety. Then, people with chronic hepatitis B received multiple doses to see how the drug behaves in the body and whether it fights the virus…
Phase: PHASE1 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Hearts from hepatitis c donors could save lives in organ shortage
Disease control CompletedThis study tests whether hearts from donors with hepatitis C can be safely transplanted into people without the virus. Twenty adults with end-stage heart failure on the transplant waiting list will receive these hearts and take antiviral medication to prevent infection. The goal …
Phase: PHASE2 • Sponsor: Mary E. Keebler, MD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Smart tags and a phone app could boost hepatitis c treatment success
Disease control CompletedThis trial tests a smartphone app called Tappt that uses smart tags to help people with hepatitis C stick to their daily oral medication. Participants scan tags each time they take a dose, and the app tracks adherence. The study compares their results to historical data from simi…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a blood pressure drug reverse liver damage in hepatitis c?
Disease control CompletedThis study tested whether adding prazosin, a drug usually used for high blood pressure, to standard hepatitis C treatment could reduce liver scarring. 112 adults with chronic hepatitis C (genotype 1 or 4) and severe liver fibrosis took part. Researchers measured changes in liver …
Phase: PHASE2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to clear hepatitis b and d in 20-patient trial
Disease control CompletedThis early-stage study tested a new treatment approach for adults with chronic hepatitis B or D. Twenty participants received two medications in sequence: P1101 (a type of interferon) followed by an anti-PD1 drug. The main goal was to check safety and tolerability, while also loo…
Phase: PHASE1 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a simple tablet stop Travelers' diarrhea before it starts?
Disease control CompletedThis study tested whether a daily dose of Travelan (IMM-124E) tablets could prevent moderate-to-severe diarrhea in healthy adults deliberately infected with ETEC bacteria, a common cause of travelers' diarrhea. Sixty-three volunteers took either Travelan or a placebo for 7 days. …
Phase: PHASE2 • Sponsor: Immuron Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for tough hepatitis c cases: triple therapy shows promise
Disease control CompletedThis study tested a combination of three drugs—Grazoprevir/Elbasvir, Sofosbuvir, and Ribavirin—in 26 adults with hepatitis C genotype 1 or 4 who had not been cured by previous treatments. The goal was to see if 16 or 24 weeks of this therapy could clear the virus. The main measur…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a flavonoid combo reverse liver scarring and prevent cancer in hepatitis b?
Disease control CompletedThis completed phase 4 trial tested whether adding SB Flavon (a blend of flavonoids, vitamin C, and L-arginine) to standard Tenofovir therapy can reverse advanced liver scarring (cirrhosis) and prevent liver cancer in 134 people with chronic hepatitis B. The study measured liver …
Phase: PHASE4 • Sponsor: Trieu, Nguyen Thi, M.D. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hepatitis c drug combo shows promise in early trial
Disease control CompletedThis study tested whether a new form of interferon (IFN alfa-2b XL) combined with ribavirin works better and causes fewer side effects than the standard treatment for chronic hepatitis C (genotypes 1 or 4). 84 adults who had not been treated before or had not responded to previou…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New study tests better ways to link former inmates to HIV and addiction treatment
Disease control CompletedThis study tested two different approaches to help people recently released from jail or prison get connected to care for HIV, hepatitis C, STIs, and opioid use disorder. Over 600 adults took part. The goal was to see which method worked better for starting and staying on treatme…
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cholera drug could cut antibiotic use and hospital stays
Disease control CompletedThis study tested a new drug called VR-AD-1005 for treating severe diarrhea caused by cholera. The drug aims to reduce fluid loss and the need for antibiotics, which could help fight antibiotic resistance. 150 adults with cholera took part, and researchers measured stool output a…
Phase: PHASE2 • Sponsor: Hunazine Biotech S.L. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Diet showdown: mediterranean vs DASH for fatty liver
Disease control CompletedThis study tested whether Mediterranean or DASH diets improve liver function in people with nonalcoholic fatty liver disease (NAFLD). 75 adults with mild to moderate liver enzyme elevations were split into three groups: one following general dietary guidelines, one on a Mediterra…
Phase: NA • Sponsor: University of Lahore • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to tame hepatitis b in HIV patients
Disease control CompletedThis Phase 2 trial tested an oral drug called selgantolimod in 29 adults with both chronic hepatitis B and HIV. Participants had been on stable antiviral therapy for both viruses for at least 5 years. The study aimed to see if the drug is safe and can lower hepatitis B surface an…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to cure hepatitis b without lifelong pills
Disease control CompletedThis Phase 3 trial tests a drug called bepirovirsen in nearly 1,000 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough that participants can safely stop all hepatitis B medications and re…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Second chance: new combo tackles hepatitis c in HIV patients
Disease control CompletedThis study tested a combination of peginterferon alfa2a and ribavirin in 17 HIV-positive people with chronic hepatitis C who had not responded to earlier treatment. Participants received weekly injections and daily pills for 48 weeks. The main goal was to see if the virus became …
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug aims to free hepatitis b patients from daily pills
Disease control CompletedThis Phase 3 study tests bepirovirsen, an experimental drug, in 857 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough to allow patients to stop all hepatitis B treatments and remain viru…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New injection aims to tame chronic hepatitis b
Disease control CompletedThis study tests an experimental drug called AHB-137 in healthy volunteers and people with chronic hepatitis B who are already on antiviral medication. The goal is to check if the drug is safe and shows early signs of controlling the virus. About 129 participants will receive eit…
Phase: PHASE1, PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
One-Stop care: hepatitis c treatment may curb HIV and opioid risks
Disease control CompletedThis study tested a new way to care for people who inject drugs and have hepatitis C. Along with standard hepatitis C treatment, participants were offered HIV prevention medication and buprenorphine for opioid use disorder. The goal was to see if this combined approach could cure…
Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Washing therapy dogs may keep hospital germs away from kids
Disease control CompletedThis study tested whether cleaning therapy dogs with a special disinfectant (chlorhexidine) before hospital visits could reduce the spread of harmful germs to children. The trial involved 45 children aged 3 to 17 who interacted with therapy dogs. Researchers checked if the cleani…
Phase: PHASE4 • Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill combo aims to tame hepatitis d in small trial
Disease control CompletedThis completed Phase 3 trial tested a once-daily combination of two drugs, lonafarnib and ritonavir, in 10 adults with chronic hepatitis D. The goal was to see if the regimen is safe and can lower the amount of virus in the blood over 48 weeks of treatment and 24 weeks of follow-…
Phase: PHASE3 • Sponsor: Soroka University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New vaccine combo aims to tame chronic hepatitis b
Disease control CompletedThis phase 2b trial tested a combination of two experimental vaccines (VTP-300) plus a low dose of the cancer drug nivolumab in 121 adults with chronic hepatitis B who were already on antiviral medication. The goal was to see if the treatment could significantly lower hepatitis B…
Phase: PHASE2 • Sponsor: Barinthus Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Hepatitis c donor livers safely transplanted into healthy recipients
Disease control CompletedThis study tested whether livers from donors with hepatitis C could be safely transplanted into people without hepatitis C. Five patients on the liver transplant waiting list received these livers and were then treated with an antiviral drug to prevent infection. The goal was to …
Phase: PHASE2 • Sponsor: Fernanda P Silveira, MD, MS • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo aims to free hepatitis b patients from daily pills
Disease control CompletedThis Phase 2 study tested an experimental drug called AB-729 combined with pegylated interferon and standard antiviral pills in 43 adults with chronic hepatitis B. The goal was to see if this approach could safely lower hepatitis B surface antigen levels and allow some participan…
Phase: PHASE2 • Sponsor: Arbutus Biopharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New way to deliver c. diff treatment: through a colonoscopy
Disease control CompletedThis study tested a treatment called RBX2660 (REBYOTA) for people with recurrent Clostridioides difficile infection. The treatment is made from healthy human stool bacteria and was given during a colonoscopy. The goal was to see if this delivery method is safe and works well. For…
Phase: PHASE3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for hepatitis b: experimental combo aims to clear the virus
Disease control CompletedThis study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on ant…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Should cancer patients get antibiotics for a dubious c. diff test? small trial seeks answers
Disease control CompletedThis study looked at whether giving the antibiotic vancomycin helps cancer patients who have diarrhea and a positive screening test for C. difficile but a negative toxin test. Only 9 patients were enrolled, far fewer than planned. Researchers measured changes in C. difficile leve…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for hepatitis b: experimental drug shows promise in mid-stage trial
Disease control CompletedThis study tested an experimental drug called VIR-2218 in 84 adults with chronic hepatitis B. Some participants received VIR-2218 alone, and others got it combined with pegylated interferon. The main goals were to check safety and how well the drug works against the virus. The st…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could adding calcium to ORS stop diarrhea faster?
Disease control CompletedThis study tested whether an oral rehydration solution (ORS) with added calcium works better than standard ORS for adults with severe watery diarrhea, including cholera. Researchers measured stool output, diarrhea duration, and other symptoms in 396 adults. The goal is to find a …
Phase: PHASE2, PHASE3 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Blood pressure drug may halt liver damage in hep c patients
Disease control CompletedThis study tested whether irbesartan, a blood pressure medication, can slow the progression of liver scarring (fibrosis) in adults with chronic hepatitis C who cannot take or did not respond to antiviral therapy. Over two years, 166 participants took either irbesartan or a placeb…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Quick HCV treatment with peer support boosts cure rates for drug users
Disease control CompletedThis study tested whether offering rapid hepatitis C treatment with help from a peer mentor (someone who has been cured) works better than the usual referral to an outside clinic. 198 people who use drugs and were in an opioid treatment program took part. The goal was to see if m…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New pill aims to tame chronic hepatitis b
Disease control CompletedThis early-stage trial tests AB-101, an oral drug that blocks a protein called PD-L1 to help the immune system fight the hepatitis B virus. The study involves 128 people, including healthy volunteers and patients with chronic hepatitis B. Researchers are primarily checking for sa…
Phase: PHASE1 • Sponsor: Arbutus Biopharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope: hepatitis c drugs after liver cancer treatment
Disease control CompletedThis study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…
Phase: PHASE3 • Sponsor: National Hepatology & Tropical Medicine Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New triple therapy aims to clear hepatitis c before liver transplant
Disease control CompletedThis study tested a combination of three drugs (pegylated interferon, ribavirin, and boceprevir) in 58 adults with genotype 1 hepatitis C and cirrhosis who were waiting for a liver transplant. The goal was to see if the treatment could clear the virus before surgery. The study me…
Phase: PHASE2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for HIV patients with Hard-to-Treat hepatitis c
Disease control CompletedThis study tested a more intensive hepatitis C treatment in 58 adults who have both HIV and hepatitis C (genotypes 1 or 4) and had not responded to previous therapy. Participants received higher doses of two drugs, peginterferon alfa-2a and ribavirin, for up to 18 months. The goa…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Dietary change may curb recurrent c. diff in cancer patients
Disease control CompletedThis study tested whether eating less fat and more fiber can reduce the chance of a repeat Clostridioides difficile infection in cancer patients. Eight participants with leukemia, lymphoma, or other cancers followed a specific diet. Researchers tracked diarrhea and measured C. di…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
HIV patients with liver failure get new drug combo tested in transplant study
Disease control CompletedThis study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection …
Phase: PHASE1, PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can vitamin d boost hepatitis c treatment in tough cases?
Disease control CompletedThis study looked at whether adding vitamin D to standard hepatitis C treatment could help patients with genotype 1 or 4 who had not responded to previous therapy. 32 adults with low vitamin D levels were enrolled. The goal was to see if vitamin D could make the antiviral drugs w…
Phase: PHASE2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hepatitis b drug shows early promise in small trial
Disease control CompletedThis early-stage trial tested an experimental injection called HH-006 in 36 adults with untreated chronic hepatitis B. The study aimed to check the drug's safety, how the body processes it, and whether it can lower virus levels. Participants received either HH-006 or a placebo ov…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Radioactive oil injection may keep liver cancer at bay
Disease control CompletedThis phase 3 trial tested whether a single injection of radioactive lipiodol (Lipiocis) into the liver artery could prevent hepatocellular carcinoma from coming back after surgery or ablation. The study enrolled 73 adults with cirrhosis and one or two liver tumors that had been s…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
DNA vaccine could help hepatitis b patients stop daily pills
Disease control CompletedThis study tests whether a DNA vaccine can help people with chronic hepatitis B control the virus after they stop taking standard antiviral drugs. The vaccine aims to boost the immune system to delay the virus from becoming active again. The trial involves 70 adults who have unde…
Phase: PHASE1, PHASE2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for HIV patients with Hard-to-Treat hepatitis c
Disease control CompletedThis phase 2 study tested a combination of three drugs—telaprevir, peginterferon, and ribavirin—in 70 adults with both HIV and hepatitis C who had not been helped by standard treatment before. The goal was to see if this triple therapy could clear the hepatitis C virus from the b…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Gut bacteria capsules take on superbugs in antibiotic patients
Disease control CompletedThis study tested whether taking capsules containing healthy gut bacteria could help clear drug-resistant germs (including C. difficile) from the intestines of 42 hospitalized adults who needed at least 7 days of antibiotics. Participants received either the bacteria capsules or …
Phase: PHASE1, PHASE2 • Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New antibody shows promise against rare liver infection
Disease control CompletedThis study tested an experimental drug called HH-003 in 101 adults with chronic hepatitis delta, a serious liver disease. HH-003 is an antibody that targets hepatitis B virus, which is needed for hepatitis delta to survive. Participants received either a low or high dose of HH-00…
Phase: PHASE2 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New antibiotic CRS3123 takes on c. diff in early trial
Disease control CompletedThis phase 2 study tested an experimental antibiotic called CRS3123 against the standard treatment vancomycin for Clostridioides difficile infection (C. diff). 43 adults with a first episode or first recurrence of C. diff took either CRS3123 or vancomycin for 10 days. The main go…
Phase: PHASE2 • Sponsor: Crestone, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Poop pills? fecal transplants show promise for gut infections
Disease control CompletedThis study tested fecal microbiota transplant (FMT) in 24 adults with recurrent Clostridium difficile infection (C. diff) that didn't get better with standard antibiotics. FMT involves placing healthy donor stool into the patient's colon to restore good bacteria. The goal was to …
Phase: PHASE4 • Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Bangkok project tests Same-Day hepatitis c care in community centers
Disease control CompletedThis completed study tested a same-day approach to hepatitis C testing and treatment in community organizations in Bangkok, Thailand. It involved 200 adults who tested positive for hepatitis C antibodies. The goal was to see if offering immediate treatment with direct-acting anti…
Phase: NA • Sponsor: Institute of HIV Research and Innovation Foundation, Thailand • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo shows promise against deadly gut infection
Disease control CompletedThis study tested whether adding the drug bezlotoxumab to standard treatment could prevent serious outcomes in people with a severe C. diff infection. Researchers used a special score to identify 44 high-risk patients. The goal was to see if the drug reduced organ failure, infect…
Phase: PHASE2 • Sponsor: Hellenic Institute for the Study of Sepsis • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for bleeding risk in hepatitis b patients?
Disease control CompletedThis study tested the drug eltrombopag in 48 Chinese adults with chronic hepatitis B and a bleeding disorder called immune thrombocytopenia (low platelets). The goal was to see if taking eltrombopag for 6 to 22 weeks could safely raise platelet counts. The trial is complete, but …
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for hepatitis b: experimental combo aims to silence the virus
Disease control CompletedThis early-stage trial tested two experimental drugs, tobevibart and elebsiran, alone or with standard treatments, in 33 adults with chronic hepatitis B. The goal was to see if these combinations could safely suppress the virus and reduce hepatitis B surface antigen levels. The s…
Phase: PHASE1, PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Mobile van brings HIV prevention and treatment directly to drug users
Disease control CompletedThis study tested whether a mobile care van linked to a needle exchange program could improve HIV prevention and treatment for people who inject drugs. 720 participants received services like HIV testing, treatment, and risk reduction through the van. The goal was to see if this …
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New pill aims to silence hepatitis b virus in patients with stubborn Low-Level infection
Disease control CompletedThis study tested a new drug called TQA3605 in 122 adults with chronic hepatitis B who still had low levels of virus despite standard treatment. Participants took either TQA3605 or a placebo alongside their usual antiviral pills for 24 weeks. The goal was to see if adding TQA3605…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New vaccine combo aims to tame chronic hepatitis b
Disease control CompletedThis early-stage trial tested two experimental therapeutic vaccines, GS-2829 and GS-6779, in 83 healthy people and those with chronic hepatitis B. The main goal was to check safety and tolerability, while also measuring immune responses. The vaccines are designed to help the body…
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for hepatitis c: triple therapy shows promise in untreated patients
Disease control CompletedThis study tested a new drug called MP-424 (Telaprevir) added to the standard two-drug therapy for hepatitis C. It involved 189 adults with genotype 1 hepatitis C who had never been treated before. The goal was to see if the triple combination could clear the virus from the blood…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug MP-424 shows promise against hepatitis c in early trial
Disease control CompletedThis phase 2 study tested MP-424 (Telaprevir) in 15 people with genotype 1b hepatitis C who had not been treated with interferon before. Participants took three 250 mg tablets every 8 hours for 24 weeks. The main goal was to see if the virus became undetectable 24 weeks after tre…
Phase: PHASE2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Last hope? new combo targets tough hepatitis c cases
Disease control CompletedThis phase 3 trial tested a drug called telaprevir (MP-424) combined with two standard hepatitis C drugs (peginterferon and ribavirin) in 10 people with genotype 2 hepatitis C who had not responded to previous treatment. The goal was to see if this combination could clear the vir…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for hepatitis c: experimental drug combo shows promise
Disease control CompletedThis completed Phase 3 trial tested an experimental drug called MP-424, combined with two standard hepatitis C medications (pegylated interferon and ribavirin), in 54 adults with genotype 1 hepatitis C. Participants were either new to treatment or had relapsed after previous ther…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for hepatitis c relapsers: triple therapy shows promise
Disease control CompletedThis study tested a triple-drug combination—telaprevir, peginterferon, and ribavirin—in 109 adults with genotype 1 hepatitis C whose infection returned after previous treatment. The goal was to see if the new regimen could clear the virus from the blood 24 weeks after treatment e…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Hope for hepatitis c relapsers: new Triple-Drug combo shows promise
Disease control CompletedThis study tested a new drug called MP-424 (telaprevir) added to standard therapy (peginterferon and ribavirin) for people with genotype 2 hepatitis C whose infection came back after previous treatment. The goal was to see if the combination could clear the virus for good. The tr…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for hepatitis c: triple therapy shows promise in late-stage trial
Disease control CompletedThis study tested a new drug called MP-424 combined with two standard medicines (interferon beta and ribavirin) in 74 adults with chronic hepatitis C (genotype 1 or 2). Participants either had never been treated before or had previously received interferon-based therapy. The main…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug combo shows promise against Hard-to-Treat hepatitis c
Disease control CompletedThis early-phase trial tested a new hepatitis C drug called telaprevir (MP-424) combined with two standard medications (peginterferon and ribavirin) in 20 people with genotype 1b hepatitis C. The main goals were to check safety and how the drug moves through the body. Researchers…
Phase: PHASE1 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can a higher dose of a common drug tame hepatitis c?
Disease control CompletedThis study tested whether higher doses of ursodeoxycholic acid (UDCA) could better lower liver enzymes in 596 adults with chronic hepatitis C. Participants received 150, 600, or 900 mg of UDCA daily for 24 weeks. The main goal was to see if the higher doses were more effective an…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for hard-to-treat hepatitis c: experimental combo shows promise
Disease control CompletedThis study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 32 adults with genotype 1 hepatitis C who had not responded to earlier treatment. The main goal was to see if the virus could be cleared from the blood 24 we…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hepatitis c drug shows early promise in small study
Disease control CompletedThis early-phase study tested MP-424 (telaprevir) in 10 patients with chronic hepatitis C genotype 1b. Participants took three 250 mg tablets every 8 hours for 12 weeks. The main goals were to check safety, how the drug moves through the body, and how it affects hepatitis C virus…
Phase: PHASE1 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
HIV patients get hepatitis a vaccine: does it work?
Disease control CompletedThis study looked at how safe and effective a hepatitis A vaccine is for people with HIV, aged 1 to 50. About 392 participants received two vaccine doses six months apart. Researchers checked their blood for antibodies and tracked any side effects for a month after each dose. The…
Phase: PHASE4 • Sponsor: LiuZhou People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New Two-Drug combo aims to tame chronic hepatitis b
Disease control CompletedThis completed phase 2 study tested a two-step treatment for chronic hepatitis B. First, participants received an antisense drug (bepirovirsen) for 12 or 24 weeks, followed by a targeted immunotherapy. The goal was to see if this sequence could safely improve virus control beyond…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Simple drug may cut infection risk after major gut surgery
Disease control CompletedThis study tested whether tranexamic acid, a drug that helps blood clot, can lower the chance of infection after gastrointestinal surgery. Over 3,300 adults at higher risk for complications took part. The goal was to see if the drug reduces surgical site infections compared to a …
Phase: PHASE4 • Sponsor: Bayside Health • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New shot aims to slash hepatitis b virus levels
Disease control CompletedThis study tested an experimental injection called RBD1016 in 48 adults with chronic hepatitis B who were already taking standard antiviral pills. The goal was to see if the injection could safely lower hepatitis B surface antigen (HBsAg), a marker of the virus. Participants rece…
Phase: PHASE2 • Sponsor: Suzhou Ribo Life Science Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can probiotics boost antibiotic success against gut bacteria overgrowth?
Disease control CompletedThis study looked at whether taking probiotic supplements alongside the antibiotic rifaximin helps people with SIBO feel better. 129 adults with bloating or constipation took either probiotics or a placebo for 3 months. The goal was to see if the combination reduced symptoms and …
Phase: NA • Sponsor: Pomeranian Medical University Szczecin • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New capsule aims to revive old antibiotic for gut infection
Disease control CompletedThis study tests a new delayed-release metronidazole capsule designed to release the drug directly in the colon, where C. diff bacteria live. 18 healthy adults will receive a single dose of either the new capsule or the standard tablet to compare how much drug reaches the colon v…
Phase: PHASE1 • Sponsor: Gateway Pharmaceutical LLC • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can adding interferon help clear hepatitis b virus?
Disease control CompletedThis study tested whether adding pegylated interferon alfa-2a to standard nucleoside analogue therapy could help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg). 119 adults with HBeAg-negative chronic hepatitis B who had been on nucleoside analogues f…
Phase: NA • Sponsor: José Antonio Carrion • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hepatitis b pill shows promise in early human trial
Disease control CompletedThis early-stage trial tests an experimental oral drug called ALG-000184 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it can lower hepatitis B virus levels. Participants take the drug d…
Phase: PHASE1 • Sponsor: Aligos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Rural patients get Hospital-Level care at home in landmark trial
Disease control CompletedThis study looked at whether giving hospital-level care to acutely ill adults in their own homes in rural areas works well. 160 people with various conditions like infections, heart failure, or COPD took part. The goal was to see if this approach could lower costs and help patien…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New pill combo aims to cure hepatitis c in just 8 weeks
Disease control CompletedThis study tested a new combination of two antiviral pills, bemnifosbuvir and ruzasvir, taken once daily for 8 weeks in 275 adults with chronic hepatitis C. The main goal was to see if the virus was still undetectable 12 weeks after treatment ended. The trial is now complete, and…
Phase: PHASE2 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New shot aims to silence hepatitis b virus
Disease control CompletedThis study tested an experimental drug called ARO-HBV in healthy volunteers and people with chronic hepatitis B. The drug uses RNA interference to try to stop the virus from multiplying. The main goal was to check safety and how the body processes the drug, not yet to prove it wo…
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Spirulina-Based drug shows promise against food poisoning
Disease control CompletedThis study tested a new oral treatment called LMN-101, made from spirulina, to see if it can prevent or control Campylobacter infection. Healthy volunteers took LMN-101 or a placebo for two days, then were exposed to the bacteria. The goal was to check safety and how well the tre…
Phase: PHASE2 • Sponsor: Lumen Bioscience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
DNA vaccine trial aims to wake up immune system against hepatitis b
Disease control CompletedThis early-stage trial tested a DNA vaccine in 10 adults with chronic hepatitis B who had not responded to standard treatments. The vaccine was designed to train the immune system to fight the virus. The main goal was to check safety, with a secondary goal of seeing if the vaccin…
Phase: PHASE1 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New cocktail of drugs shows promise in hepatitis b trial
Disease control CompletedThis study tested several new drug combinations in 281 people with chronic hepatitis B who were already on standard antiviral therapy. The goal was to see if adding experimental drugs could clear a key virus marker (HBsAg) from the blood. Participants received different combinati…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 26, 2026 18:59 UTC
-
Kidney-Friendly? early study checks hepatitis d drug in patients with impaired kidneys
Disease control CompletedThis early-stage study looked at how the drug bulevirtide behaves in people with chronic hepatitis D who also have normal or impaired kidney function. Researchers measured drug levels in the blood, its effect on bile acids, and overall safety. The study enrolled 41 adults and gav…
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 26, 2026 18:26 UTC
-
Hepatitis c care at opioid clinics boosts treatment access
Disease control CompletedThis study tested whether offering hepatitis C treatment at the same clinic where people receive opioid therapy leads to better outcomes than referring them to a separate infectious disease clinic. About 298 people on opioid therapy with chronic hepatitis C took part. The goal wa…
Phase: NA • Sponsor: Haukeland University Hospital • Aim: Disease control
Last updated Jun 26, 2026 17:34 UTC
-
Herbal blend shows promise against COVID-19 in small trial
Disease control CompletedThis completed Phase 4 trial tested a herbal supplement called AntiCov-220 in 82 people with underlying health conditions, including HIV and cancer. The goal was to see if it could prevent and treat COVID-19 by boosting the immune system and fighting the virus. The study compared…
Phase: PHASE4 • Sponsor: Nguyen Thi Trieu, MD • Aim: Disease control
Last updated Jun 26, 2026 16:25 UTC
-
New rapid test for infection and inflammation put to the test
Diagnosis CompletedThis study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New hepatitis b blood tests put to the test on 21,000 samples
Diagnosis CompletedThis study checked how well new blood tests (Access HBV assays) can detect hepatitis B infection. Researchers tested over 21,000 leftover blood samples from adults, including blood donors and hospital patients. The goal was to see if these tests are accurate compared to existing …
Sponsor: Beckman Coulter, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
New blood test may spot liver cancer earlier in hepatitis c patients
Diagnosis CompletedThis study looked at whether measuring tiny molecules called microRNAs in the blood can help diagnose liver cancer (hepatocellular carcinoma) in people with hepatitis C. Researchers tested blood samples from 84 participants, including healthy people and those with hepatitis C, wi…
Sponsor: Benha University • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
New PET scan technique aims to sniff out hidden infections
Diagnosis CompletedThis early study tested whether a special PET scan using a radioactive form of vitamin B9 (11C-PABA) can help doctors see infections deep inside the body. Researchers scanned 13 healthy people and patients with known or suspected infections. The goal was to see if this method can…
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New MRI scan could replace liver biopsies
Diagnosis CompletedThis study tested how well a special MRI scan called LiverMultiScan can measure liver fat, iron, and scarring. 61 adults with various liver diseases had up to 6 scans on different machines. The goal was to see if the results are consistent when repeated on the same scanner or on …
Sponsor: Perspectum • Aim: Diagnosis
Last updated Jun 27, 2026 08:00 UTC
-
New rapid tests aim to stop STIs in their tracks for pregnant women in zimbabwe
Diagnosis CompletedThis study tested a strategy of using rapid, point-of-care diagnostic tests for sexually transmitted infections (STIs) in pregnant women attending antenatal clinics in Zimbabwe. Over 1,000 women were offered testing for chlamydia, gonorrhea, trichomoniasis, syphilis, and hepatiti…
Phase: NA • Sponsor: London School of Hygiene and Tropical Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
App and peer support aim to boost HIV prevention for people leaving jail
Prevention CompletedThis study tested whether a mobile app (GeoPassport), financial incentives, and peer mentor support could help men who have sex with men and transgender women leaving jail access HIV prevention services like PrEP and testing. 233 participants were enrolled and followed for 9 mont…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Prevention
Last updated Jun 27, 2026 12:35 UTC
-
Simple combo could stop hepatitis b passed from mom to baby
Prevention CompletedThis study tested whether giving pregnant women with hepatitis B a daily pill (tenofovir) plus giving their newborns a hepatitis B vaccine at birth could safely prevent the virus from passing to the baby. The trial enrolled 317 women in the Democratic Republic of Congo and follow…
Phase: PHASE4 • Sponsor: University of North Carolina, Chapel Hill • Aim: Prevention
Last updated Jun 27, 2026 09:06 UTC
-
Real-world data shows REBYOTA™ may stop c. diff from coming back
Prevention CompletedThis observational study followed 145 adults who received REBYOTA™ to prevent another Clostridioides difficile infection (CDI) after completing antibiotics. Researchers collected information from medical records over 6 months to see how many people stayed infection-free. The goal…
Sponsor: Ferring Pharmaceuticals • Aim: Prevention
Last updated Jun 27, 2026 09:00 UTC
-
Could a simple antibiotic taper stop c. diff relapse?
Prevention CompletedThis study tested whether extending standard vancomycin treatment for C. diff infection with a 2-week taper (lowering the dose gradually) reduces the chance of the infection returning. 263 adults who had a first episode or first recurrence of C. diff were randomly assigned to rec…
Phase: PHASE3 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
Stool transplant plus antibody drug shows promise against recurrent c. diff in IBD patients
Prevention CompletedThis study tested whether combining a fecal microbiota transplant (FMT) with the drug bezlotoxumab could prevent repeat Clostridium difficile infections in people with inflammatory bowel disease (IBD). Sixty-one adults with at least two prior C. diff infections were randomly assi…
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
UV water treatment tested to keep kids healthy
Prevention CompletedThis study tested whether treating private well water with ultraviolet (UV) light can prevent stomach and respiratory infections in children under 5. Researchers gave 28 Pennsylvania households either a real UV device or a fake one and tracked illness symptoms via weekly texts. T…
Phase: NA • Sponsor: Temple University • Aim: Prevention
Last updated Jun 26, 2026 14:41 UTC
-
Could a daily supplement soothe SIBO? small trial tests safety
Symptom relief CompletedThis pilot study tested an 8-week course of a multi-ingredient nutritional supplement (AV1PD1A) in 9 adults with hydrogen-dominant small intestinal bacterial overgrowth (SIBO). The main goal was to see if the supplement was safe and tolerable. Participants took three capsules dai…
Phase: NA • Sponsor: National University of Natural Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Can an online wellness program ease anxiety in chronic disease?
Symptom relief CompletedThis study tested a 12-week online mind-body program for adults with chronic conditions like heart failure, cancer, and liver disease. The program included mindful movement, meditation, breathwork, and coping skills. Researchers measured changes in anxiety, depression, fatigue, a…
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Low FODMAP diet eases gut troubles in SIBO patients
Symptom relief CompletedThis study looked at whether a low FODMAP diet (LFD) can reduce stomach symptoms and improve nutrition in people with small intestinal bacterial overgrowth (SIBO). 51 adults who had finished antibiotic treatment were split into two groups: one followed the LFD, the other ate norm…
Phase: NA • Sponsor: Warsaw University of Life Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Probiotic cocktail cuts diarrhea duration in young kids
Symptom relief CompletedThis study tested whether a mix of two probiotics (Lactobacillus acidophilus and Limosilactobacillus reuteri) could shorten diarrhea in children aged 1 to 6 with acute infectious diarrhea. 145 children were randomly assigned to receive the probiotics or a placebo. Researchers mea…
Phase: NA • Sponsor: Eskisehir Osmangazi University • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Simple tricks may soothe baby vaccine pain
Symptom relief CompletedThis study tested two simple methods—mechanical vibration and flick tapping—to reduce pain in 80 infants receiving their second hepatitis B vaccine. Babies were randomly assigned to one of the two techniques, and researchers measured pain scores, crying time, and vital signs. The…
Phase: NA • Sponsor: Berrin GOGER • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
Knowledge-focused CompletedThis study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Blood donors help unlock secrets of hepatitis c
Knowledge-focused CompletedThis study looked at 805 blood donors who tested positive for hepatitis C virus (HCV) to learn how the virus spreads and affects health over time. Researchers collected blood samples and health information to track infection and liver disease. The goal was to better understand HC…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Hepatitis b drug holiday: study tests if stopping pills is safe
Knowledge-focused CompletedThis study tested whether people with chronic hepatitis B who had been on antiviral drugs for at least 4 years could safely stop treatment. Fifteen adults were monitored with monthly blood tests for 6 months after stopping, then every 3 months. The goal was to see if the virus st…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Hepatitis c study tests whether a patient registry is possible in vietnam
Knowledge-focused CompletedThis study looked at whether it's possible to create a group of people with hepatitis C in Hai Phong, Vietnam, for future research. 300 adults with active hepatitis C took part. The goal was to see how many patients could be enrolled and how much information could be collected, n…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Hidden hepatitis e threat in transplant patients?
Knowledge-focused CompletedThis study checked how many organ transplant recipients in the U.S. have antibodies to the hepatitis E virus, which can become chronic in people with weakened immune systems. Researchers enrolled 447 adults who had a liver, kidney, or small bowel transplant or were on a waiting l…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Hepatitis b mutations linked to higher virus levels
Knowledge-focused CompletedThis study looks at how certain genetic changes (mutations) in the hepatitis B virus (HBV) affect the amount of virus in the blood of people with chronic infection. Researchers analyzed blood samples from 92 patients not on antiviral treatment. They found that specific mutations …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Zambia study tracks hepatitis b outcomes in hundreds of patients
Knowledge-focused CompletedThis study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Should older hepatitis b patients with normal ALT get antivirals? new study explores
Knowledge-focused CompletedThis study followed 250 chronic hepatitis B patients over age 30 who had detectable virus but normal liver enzyme levels (ALT). All had never received antiviral treatment before. Researchers measured how many became virus-negative after 48 weeks of antiviral therapy, and how many…
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New study tests faster hepatitis c detection for drug users
Knowledge-focused CompletedThis study looked at two faster ways to test for hepatitis C in people who recently injected drugs and visit needle exchange programs. One method uses a fingerstick test with results in about an hour, and the other uses a dried blood spot sent to a lab. The goal was to see if the…
Phase: NA • Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Are cirrhosis patients getting the shots they need? french study finds out
Knowledge-focused CompletedThis study looked at how many people with cirrhosis in French general hospitals were vaccinated against diseases like hepatitis, flu, and COVID-19. Researchers surveyed 742 patients to see if they were up to date on their shots. The goal was to find gaps in vaccination coverage s…
Sponsor: Centre Hospitalier Sud Francilien • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Do fish workers get more allergies? new study investigates
Knowledge-focused CompletedThis completed study looked at how common fish allergy is among people who work with fish, like fishermen and fish-processing factory workers, compared to other workers. Researchers surveyed 486 people in Boulogne-sur-Mer, France, asking about allergic symptoms and exposure to fi…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Bodyweight workouts in school boost teen fitness
Knowledge-focused CompletedThis study tested whether adding calisthenics (bodyweight exercises like push-ups and squats) to gym class helps teens get stronger and feel better about themselves. 100 students aged 13-16 were split into two groups: one did calisthenics for 12 weeks, the other followed standard…
Phase: NA • Sponsor: Universitat de Lleida • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Quick hepatitis c test during mammograms could catch hidden cases
Knowledge-focused CompletedThis study offered a rapid hepatitis C test to 1,500 women aged 50-74 who were already coming in for breast cancer screening in Montpellier, France. The goal was to see how many women would agree to the extra test and how many had undiagnosed hepatitis C. Women who tested positiv…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New ultrasound technique aims to better measure liver health
Knowledge-focused CompletedThis study tested a new ultrasound technique called ARFI to measure liver stiffness in 109 people, including healthy volunteers and patients with liver conditions. The goal was to understand normal stiffness values and how they change with disease or treatment. This is an observa…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Guadeloupe liver infection study reveals key bacterial culprits
Knowledge-focused CompletedThis completed study looked at 58 adults in Guadeloupe with pyogenic liver abscesses, a serious bacterial infection of the liver. Researchers identified the bacteria responsible and tested their antibiotic resistance. The goal was to understand local causes and improve treatment,…
Sponsor: Centre Hospitalier Universitaire de la Guadeloupe • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Gut bacteria may worsen liver disease – new study investigates
Knowledge-focused CompletedThis study looked at how bacteria from the gut might travel to the liver and make liver disease worse in people with hepatitis C. Thirty adults with stable liver disease took part. Researchers used blood tests, MRI scans, and liver tissue samples to measure bacterial movement and…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Hepatitis & liver cancer risk explored in immigrant communities
Knowledge-focused CompletedThis study tested 892 African and Asian immigrants for hepatitis B and C to understand how these infections raise the risk of liver cancer. Researchers also checked vaccination rates and tracked new cancer cases over time. No treatment was given; the goal was to gather informatio…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Stress and depression may worsen liver disease in korean americans with hepatitis b
Knowledge-focused CompletedThis study looked at how factors like chronic stress and depression might speed up liver damage in Korean Americans with chronic hepatitis B. Researchers followed 365 participants over time, collecting health records, hair samples, and interview data. The goal was to understand w…
Sponsor: Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver disease Patients' vaccine response under the microscope
Knowledge-focused CompletedThis study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. About 233 adults had three visits over a year to check their immune response and see if they got COVID-19. The goal was to understand if liver disease af…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Dundee study tests if HCV treatment stops spread among drug users
Knowledge-focused CompletedThis study looked at whether treating hepatitis C in people who inject drugs can prevent the virus from spreading to others. Researchers analyzed health records of about 2,800 people in NHS Tayside who were tested or treated for hepatitis C. No new treatments or procedures were g…
Sponsor: University of Dundee • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
450 transgender people join landmark health study in southeast asia
Knowledge-focused CompletedThis study followed 450 transgender people (300 HIV-negative and 150 living with HIV) from community health centers in Thailand, Vietnam, and the Philippines for 24 months. Researchers tracked new HIV infections, mental health, and social factors like stigma and violence using su…
Sponsor: Institute of HIV Research and Innovation Foundation, Thailand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Scientists map gut bugs in double infection
Knowledge-focused CompletedThis study looked at 42 adults with both H. pylori infection and small intestinal bacterial overgrowth (SIBO). Researchers used advanced DNA and chemical tests on stool samples to map the types of gut bacteria and their byproducts. The goal was to better understand how these two …
Sponsor: Zhongshan Hospital (Xiamen), Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Can a virtual community curb Opioid-Linked HIV and hepatitis c in rural america?
Knowledge-focused CompletedThis study tested a digital, community-led program to help people in rural Appalachia and the Midwest reduce their risk of HIV and hepatitis C, often linked to opioid use. Over 500 adults took part, with half currently or previously using illicit substances. The program included …
Phase: NA • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Antibiotics may temporarily alter gut nerve cells, new study finds
Knowledge-focused CompletedThis study looked at how a short course of antibiotics changes the nerve and glia cells in the lower gut of 10 healthy adults. Researchers took colon tissue samples before and after antibiotic treatment to count these cells and measure gene activity. The goal was to understand if…
Phase: PHASE4 • Sponsor: Rockefeller University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New Free-Breathing MRI could make liver scans easier for kids
Knowledge-focused CompletedThis study tested new MRI and MRE techniques that let children breathe normally during scans, instead of holding their breath. The goal was to measure liver fat and stiffness more comfortably and accurately in kids with fatty liver disease. 135 children aged 6-17 took part, and t…
Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Study uncovers hurdles to hepatitis b care for immigrants in the US
Knowledge-focused CompletedThis completed study looked at 274 foreign-born adults in the US with chronic hepatitis B to understand why many do not get proper follow-up care. Participants completed a one-time survey about their background, immigration experience, and healthcare access. The goal is to identi…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New app could boost emergency care in remote uganda
Knowledge-focused CompletedThis study tested a mobile app called OASES that guides nurses and clinical officers in rural Uganda through emergency care steps for severe diarrhea, breathing problems, and seizures. About 15 clinicians used the app during simulated patient scenarios to see if it helped them fo…
Phase: NA • Sponsor: University of Milano Bicocca • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Early safety check for new c. diff drug in japanese volunteers
Knowledge-focused CompletedThis early-stage study tested a single dose of AZD5148, a potential treatment for C. difficile infection, in 16 healthy Japanese adults. The main goal was to see if the drug is safe and how the body processes it. Participants received either the drug or a placebo by injection and…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Liver drug bulevirtide tested in people with liver problems
Knowledge-focused CompletedThis completed Phase 1 study looked at how the drug bulevirtide (Hepcludex) behaves in the body of people with normal liver function and those with liver impairment. Researchers measured drug levels in the blood and how quickly it is cleared. The study involved 74 participants an…
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Zambia hepatitis b survey reveals who needs treatment
Knowledge-focused CompletedThis study looked at over 5,000 adults in Zambia to find out how many have hepatitis B and how many need treatment. Researchers tested people in their homes and then did more tests on those who tested positive. The goal was to gather information, not to test a new treatment or cu…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Cleaner toilets, stronger vaccine? study tests Sanitation's role
Knowledge-focused CompletedThis study looked at whether having better sanitation helps the oral rotavirus vaccine work better in babies. Researchers followed 261 infants in low-income areas of Maputo, Mozambique, comparing those with improved sanitation to those without. They measured immune response and c…
Sponsor: London School of Hygiene and Tropical Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Breath test reveals gut bacteria changes after Weight-Loss surgery
Knowledge-focused CompletedThis study looked at how gastric bypass surgery changes the bacteria in the small intestine. Researchers measured hydrogen in the breath of 51 severely obese patients before surgery and at several points up to 2 years after. The goal was to find out how often bacterial overgrowth…
Phase: NA • Sponsor: Lille Catholic University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Are future doctors protected? study checks hepatitis b and chickenpox immunity in med students
Knowledge-focused CompletedThis study looked at how many medical students have immunity against hepatitis B and varicella-zoster (chickenpox) viruses. Researchers tested 401 students to see their protection levels and vaccination rates. The goal was to understand if current immunization programs are workin…
Sponsor: Thammasat University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Rapid tests reveal hidden infections in detention centers
Knowledge-focused CompletedThis study tested 350 detainees in Nîmes, France for HIV, hepatitis B, and hepatitis C using rapid diagnostic tests. Many detainees come from areas where these infections are common and often don't know their status. The goal was to find out how many are infected so that care can…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Can your immune system predict a c. diff relapse?
Knowledge-focused CompletedThis study looked at how the immune system responds to Clostridium difficile infection in hospitalized patients. Researchers took blood samples every two days to measure immune markers. The goal was to find out why some patients have repeat infections. The study involved 56 parti…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Tiny study aims to improve c. diff sample collection
Knowledge-focused CompletedThis study looked at how well stool and blood samples could be collected from 7 adults with an active C. diff infection. Researchers wanted to see if the collection, shipping, and testing methods worked smoothly. Participants also filled out questionnaires about their symptoms. T…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
ICU antibiotic dosing: what really matters?
Knowledge-focused CompletedThis study looked at 156 critically ill patients to find out what factors help achieve the right levels of beta-lactam antibiotics in the blood. Researchers collected clinical data and used therapeutic drug monitoring to see which patients reached target concentrations. The goal …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
First human test of new hepatitis d drug begins
Knowledge-focused CompletedThis early-stage study tested the safety and how the body processes a new drug called ABI-6250 in 40 healthy adults. Participants received either the drug or a placebo, and researchers measured side effects and drug levels in the blood. The goal was to gather safety information b…
Phase: PHASE1 • Sponsor: Assembly Biosciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Hidden diabetes risk in hepatitis c kids?
Knowledge-focused CompletedThis observational study checked whether children with hepatitis C who also have thalassemia or survived childhood cancer are more likely to develop insulin resistance (a step toward diabetes). Researchers compared 90 infected children to healthy kids of the same age and gender. …
Sponsor: Ain Shams University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
New program aims to bridge healthcare gap for inmates with HIV and hepatitis c
Knowledge-focused CompletedThis study tested a program called CJC-TraC, where a nurse case manager helps incarcerated individuals with HIV, hepatitis C, or substance use disorder prepare for release and connect to community healthcare. The program involved up to 4 in-person or telehealth visits before rele…
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Study reveals hidden fat in liver and pancreas of hepatitis b patients
Knowledge-focused CompletedThis completed study looked at 217 adults with chronic hepatitis B to see how common fatty liver and fatty pancreas are in obese versus lean patients. Researchers used ultrasound and a special liver stiffness test to measure fat and scarring. The goal was to learn more about how …
Sponsor: Tanta University • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:09 UTC
-
Scientists hunt for hidden proteins on hepatitis b virus
Knowledge-focused CompletedThis study looked at human proteins that stick to hepatitis B virus particles in blood samples from 14 infected adults. The goal was to identify these proteins and understand how they help the virus survive and spread. This is basic research, not a treatment, but it may point tow…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:43 UTC
-
Steroids for COVID-19: hidden hepatitis b danger revealed?
Knowledge-focused CompletedThis completed study looked at whether COVID-19 patients treated with steroids might have a reactivation of hepatitis B virus (HBV). Researchers followed 1,793 hospitalized adults who needed oxygen and received steroids for COVID-19 pneumonia. The goal was to see how well doctors…
Sponsor: University Medical Centre Ljubljana • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:01 UTC
-
Tiny study looks at hepatitis c Virus's hidden protein partners
Knowledge-focused CompletedThis study aims to identify human proteins that stick to hepatitis C virus particles in patient blood samples. By understanding which proteins the virus uses to survive and spread, researchers hope to find new targets for future treatments. Ten adults with chronic hepatitis C eac…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:28 UTC